Long-term lymphoma risk in thiopurine-treated inflammatory bowel disease: A 15-year propensity-matched cohort study

Table 3 Odds ratio for lymphoma outcomes for patients with ulcerative colitis taking thiopurines vs ulcerative colitis taking 5-aminosalicylic acid and not taking thiopurines or biologics

Outcomes	Events in UC with thiopurines	Events in UC with 5-ASA	OR (95%CI)	P value
Overall lymphoma
1 year	≤ 10	≤ 10
3 years	29	15	1.94 (1.04-3.62)	0.037
5 years	38	19	2.01 (1.16-3.48)	0.016
10 years	54	26	2.08 (1.31-3.32)	0.0017
15 years	60	27	2.23 (1.41-3.50)	0.0004
Hodgkin lymphoma
1 year
3 years
5 years
10 years
15 years
Non-Hodgkin lymphoma
1 year	≤ 10	≤ 10
3 years	27	13	2.05 (1.07-3.90)	0.029
5 years	35	17	2.07 (1.16-3.69)	0.012
10 years	50	24	2.09 (1.28-3.40)	0.0024
15 years	55	25	2.20 (1.37-3.53)	0.0008
B-cell lymphoma
1 year	≤ 10	≤ 10
3 years	27	12	2.26 (1.14-4.46)	0.016
5 years	34	16	2.13 (1.18-3.86)	0.0107
10 years	50	24	2.09 (2.38-3.40)	0.0024
15 years	55	25	2.20 (1.37-3.53)	0.0008
T-cell/natural killer cell lymphoma
1 year	≤ 10	≤ 10
3 years	≤ 10	≤ 10
5 years	≤ 10	≤ 10
10 years	≤ 10	≤ 10
15 years	≤ 10	≤ 10

Odds ratios of lymphoma outcomes at the 1-year, 3-year, 5-year, 10-year, and 15-year follow-up among propensity score-matched cohorts of patients with ulcerative colitis taking thiopurines vs patients with ulcerative colitis taking 5-aminosalicylic acid and not taking thiopurines or biologics. Outcomes are presented as event counts with percentage and corresponding odds ratios with 95% confidence intervals. All analyses reflect matched sample sizes of 12334 per group. 5-ASA: 5-aminosalicylates; UC: Ulcerative colitis; OR: Odds ratio; CI: Confidence interval.